New publication with TLA confirms a significant reduction of severe exacerbations and increased Quality of Life for patients with severe allergic asthma
Airsonett announced today a new publication: “Effect of nocturnal Temperature-controlled Laminar Airflow on the reduction of severe exacerbations in patients with severe allergic asthma: a meta-analysis”1
The study concludes that nocturnal use of TLA (Temperature-controlled Laminar Airflow) shows a beneficial effect on severe exacerbations and quality of life in more symptomatic patients with severe allergic asthma. The patient group with the most severe symptoms showed a significant reduction of severe exacerbations of 48-59%, for TLA compared to placebo.
Professor Leif Bjermer, a co-author, said: "With this publication, we have further confirmed what previous studies have shown; that TLA treatment has a very good effect on both exacerbations and quality of life for multi-sensitised allergic asthma patients that are sensitive to biological stress, with symptoms that are otherwise difficult to control".
"We are indeed pleased with the results of the study, that further confirms the excellent effects on our patient group. Another important take away from this study is that TLA has a particularly good effect on patients with more severe symptoms. This relatively small patient group represents approximately 40% of asthma treatment costs in health care. We can conclude that this further positions TLA as a very cost-efficient treatment, "says Anders Due-Boje, CEO of Airsonett.
Method of the study: Patients with severe allergic asthma (GINA 4/5) were extracted from two 1-year randomised, double-blind, placebo-controlled trials conducted with TLA. A meta-analysis of the effect on severe exacerbations was performed by negative binomial regression in a sequential manner, defined by baseline markers of asthma control (symptoms and QoL scores).
1: A. J. Chauhan, T. P. Brown, W. Storrar, L. Bjermer, G. Eriksson, F. Radner, S. Peterson & J. O. Warner, European Clinical Respiratory Journal, 10 Mar 2021
2: Clinical documentation for TLA: https://airsonett.eu/clinical-...
For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu
About Airsonett
Airsonett® är ett svenskt medicintekniskt företag som är ledande inom icke-farmakologisk behandling av patienter med allergisk svår, okontrollerad astma och eksem. Airsonett® Air4 är en icke-invasiv medicinsk utrustning för hembehandling baserad på den patenterade tekniken Temperatur-reglerat laminärt luftflöde (TLA). Behandling med Airsonett® Air4 medför drastisk minskning av allergener och andra luftburna partiklar i patientens andningszon under vila och sömn. Airsonett® Air4 rekommenderas av Socialstyrelsen och Barnläkarföreningen samt ingår sedan 2015 i Läkemedelsverkets riktlinjer för astmabehandling. Airsonett® Air4 är en CE-märkt medicinteknisk utrustning, Klass 1, avsedd att användas för lindring av symtom vid allergiska sjukdomar såsom allergisk astma och eksem. Den följer relevanta EU-direktiv gällande utformning, funktion, säkerhet, hälsokrav och har genomgått rigorös klinisk forskning så väl som hälsoekonomiska analyser. Airsonett® Air4 innehar ett 510(k) godkännande, klass II, från FDA. Bolagets huvudägare är SEB Venture Capital, Industrifonden och Magnus Lundberg. För ytterligare information, besök www.airsonett.se
Powered by Notified